Literature DB >> 11141057

Epitope mapping of the transforming growth factor-beta superfamily protein, macrophage inhibitory cytokine-1 (MIC-1): identification of at least five distinct epitope specificities.

W D Fairlie1, P K Russell, W M Wu, A G Moore, H P Zhang, P K Brown, A R Bauskin, S N Breit.   

Abstract

Macrophage inhibitory cytokine-1 (MIC-1) is a divergent member of the transforming growth factor-beta (TGF-beta) superfamily whose increased expression is associated with macrophage activation and which is expressed highly in placenta as compared to other tissues. There are two known allelic forms of human MIC-1 due an amino acid substitution at position 6 of the mature protein. We have raised four monoclonal antibodies (MAbs) and one polyclonal antiserum to the mature protein region of human MIC-1 and have used an extensive panel of MIC-1 relatives, mutants, and chimeras to map their epitopes. None of the MAbs were able to cross-react with either the murine homologue of MIC-1 or with hTGF-beta1, and all of the MAb epitopes were conformation-dependent. A distinct cross-reactivity pattern with the various antigens was observed for each of the monoclonal and polyclonal antibodies suggesting the presence of at least five immunogenic regions on the MIC-1 surface. One of the MAbs is directed against the amino terminus of the protein and can distinguish between the two allelic forms of MIC-1. The epitopes for the other three MAbs were located near the tips of the so-called "fingers" of the protein and appeared to be partially overlapping as each involved amino acids in the region 24-37. In one case, it was possible to mutate murine MIC-1 so that it could be recognized by one of the MAbs. Finally, the use of another mutant in which Cys 77 was replaced by serine enabled confirmation of the location of the MIC-1 interchain disulfide bond.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11141057     DOI: 10.1021/bi001064p

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

1.  GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand.

Authors:  Linda Yang; Chih-Chuan Chang; Zhe Sun; Dennis Madsen; Haisun Zhu; Søren B Padkjær; Xiaoai Wu; Tao Huang; Karin Hultman; Sarah J Paulsen; Jishu Wang; Anne Bugge; Jane Boesen Frantzen; Per Nørgaard; Jacob Fuglsbjerg Jeppesen; Zhiru Yang; Anna Secher; Haibin Chen; Xun Li; Linu Mary John; Bing Shan; Zhenhua He; Xiang Gao; Jing Su; Kristian T Hansen; Wei Yang; Sebastian Beck Jørgensen
Journal:  Nat Med       Date:  2017-08-28       Impact factor: 53.440

2.  The H6D variant of NAG-1/GDF15 inhibits prostate xenograft growth in vivo.

Authors:  Xingya Wang; Kali Chrysovergis; Rachelle J Bienstock; Minsub Shim; Thomas E Eling
Journal:  Prostate       Date:  2011-08-01       Impact factor: 4.104

Review 3.  COX inhibitors directly alter gene expression: role in cancer prevention?

Authors:  Xingya Wang; Seung Joon Baek; Thomas Eling
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

4.  Negative regulation of gp130 signalling mediated through tyrosine-757 is not dependent on the recruitment of SHP2.

Authors:  W Douglas Fairlie; David De Souza; Nicos A Nicola; Manuel Baca
Journal:  Biochem J       Date:  2003-06-01       Impact factor: 3.857

Review 5.  The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer.

Authors:  Xingya Wang; Seung Joon Baek; Thomas E Eling
Journal:  Biochem Pharmacol       Date:  2012-12-07       Impact factor: 5.858

6.  MIC-1/GDF15 in Barrett's oesophagus and oesophageal adenocarcinoma.

Authors:  O M Fisher; A J Levert-Mignon; S J Lord; K K M Lee-Ng; N K Botelho; D Falkenback; M L Thomas; Y V Bobryshev; D C Whiteman; D A Brown; S N Breit; R V Lord
Journal:  Br J Cancer       Date:  2015-03-17       Impact factor: 7.640

7.  Association of Growth and Differentiation Factor 15 in Rheumatoid Arthritis.

Authors:  Yan-Wei He; Cheng-Song He
Journal:  J Inflamm Res       Date:  2022-02-19

8.  Integrated analyses of growth differentiation factor-15 concentration and cardiometabolic diseases in humans.

Authors:  Susanna Lemmelä; Eleanor M Wigmore; Christian Benner; Aki S Havulinna; Rachel M Y Ong; Tibor Kempf; Kai C Wollert; Stefan Blankenberg; Tanja Zeller; James E Peters; Veikko Salomaa; Maria Fritsch; Ruth March; Aarno Palotie; Mark Daly; Adam S Butterworth; Mervi Kinnunen; Dirk S Paul; Athena Matakidou
Journal:  Elife       Date:  2022-08-02       Impact factor: 8.713

9.  Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer.

Authors:  R J E Skipworth; D A C Deans; B H L Tan; K Sangster; S Paterson-Brown; D A Brown; M Hunter; S N Breit; J A Ross; K C H Fearon
Journal:  Br J Cancer       Date:  2010-01-26       Impact factor: 7.640

10.  The anorectic actions of the TGFβ cytokine MIC-1/GDF15 require an intact brainstem area postrema and nucleus of the solitary tract.

Authors:  Vicky Wang-Wei Tsai; Rakesh Manandhar; Sebastian Beck Jørgensen; Ka Ki Michelle Lee-Ng; Hong Ping Zhang; Christopher Peter Marquis; Lele Jiang; Yasmin Husaini; Shu Lin; Amanda Sainsbury; Paul E Sawchenko; David A Brown; Samuel N Breit
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.